AIM To explore the clinical effects of PCSK9 inhibitor in patients with AMI undergoing PCI.
METHODS 65 patients with AMI diagnosed in our department from 2019.01 to 2019.10 and treated with PCI were selected and randomly divided into (statins + PCSK9 inhibitors) group (n=32) and statins group (n=33). The patients were followed up for six months. The changes of low-density lipoprotein cholesterol (LDL-C), cardiovascular events and major adverse reactions were observed.
RESULTS ① Compared with the patients treated with statins alone, the total cholesterol (TC)(3.6±1.2) vs (4.4±1.0) mmol/L、triglyceride (TG) (1.4±0.7) vs (2.0±1.3) mmol/L、low density lipoprotein cholesterol (LDL-C)(0.7±0.6) vs (1.8±0.9) mmol/L、Lp (a) (198±94) vs (263±129) mg/L、apoB(0.70±0.21) vs (0.97±0.27) g/L、FFA(0.46±0.10) vs (0.53±0.14) mmol/L and PCSK9(147±70) vs (290±78) ng/ml) were significantly reduced in the group of statins combined with PCSK9 inhibitors. The results were statistically significant (all P<0.05). ② After 6 months follow-up, there was no significant difference in the main adverse cardiovascular events between the two groups. ③ After 6 months follow-up, the main adverse reactions of the two groups did not increase significantly.
CONCLUSION In patients with AMI undergoing PCI, statins combined with PCSK9 inhibitors can significantly reduce LDL-C levels, and do not increase cardiovascular events and major clinical adverse reactions.
DownLoad: